Skip to main content
Signal8

Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform

$MGRXPress releaseNov 12, 2026, 7:00 AM ETRead the release

Mangoceuticals announced a partnership with T7X to issue up to 1,000,000 shares of tokenized Series D Cumulative Convertible Preferred Stock at $10.00 per share, for gross proceeds of up to $10 million, in what it says would be the first security issued by a Nasdaq-listed company on the T7X platform. The preferred carries an 8% cumulative annual dividend on the $10.00 stated value, payable quarterly when declared. No common stock is issued at closing; conversion begins three years after issuance at a fixed price equal to 300% of the pre-qualification 10-day VWAP, subject to a floor price.

Key figures

Deal Value Usd
10000000
Offering Price
10
Shares Offered
1000000
Dividend rate
8% annual, cumulative, non-compounding, payable quarterly
Offering type
Tier 2 Regulation A (Form 1-A)
Conversion start
three years from issuance
Conversion premium
300% of 10-day VWAP preceding SEC qualification, with floor price

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.